In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine—which designs nanotechnology-based ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

The team applied this method to mRNA/saRNA constructs from 1 to 10 kb and assessed pH ranges from 3 to 6. For all the RNA constructs, the J2 immunoblot signal—a marker for dsRNA strands—decreased with ...

mRNA-3927 is an investigational novel mRNA-based therapeutic agent that is composed of two mRNAs encoding for normal human PCCA and PCCB subunits. Intravenous (IV) administration of mRNA-3927 is ...

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, in partnership ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Top pharma stocks by Quant Ratings: see Strong Buy/Buy picks across PJP/XPH/PPH—plus why Moderna surged on new cancer-trial ...

There's a potential new method to treat infertility through mRNA technology, according to Johns Hopkins Medicine research. In ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...